# Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies

**Authors:** Amrita Sandhu, Devendra K. Agrawal

PMC · DOI: 10.26502/aimr.0233 · Archives of internal medicine research · 2026-02-28

## TL;DR

Dermatomyositis is a rare autoimmune disease with skin and muscle symptoms, requiring a detailed diagnostic and treatment approach due to its complex and varied nature.

## Contribution

This review provides a comprehensive overview of dermatomyositis, emphasizing diagnostic challenges and management strategies.

## Key findings

- Dermatomyositis presents with diverse clinical phenotypes, complicating diagnosis.
- Myositis-specific autoantibodies correlate with clinical patterns and prognosis.
- Current treatments include glucocorticoids and immunosuppressive therapies, with future directions focusing on personalized approaches.

## Abstract

Dermatomyositis is a rare, inflammatory myopathy with signature cutaneous manifestation and variable degrees of muscular and systemic involvement. Clinical phenotypes range from muscle-predominant disease to amyopathic presentations, leading to diagnostic complexity and heterogeneity in disease trajectory. Immunologic testing reveals myositis-specific autoantibodies that associate with characteristic clinical patterns, pattern of organ involvement, and prognostic implications, including interstitial lung disease and malignancy. The absence of definitive serologic markers in all cases of dermatomyositis requires a comprehensive diagnostic approach integrating clinical features, supportive testing, and histopathologic evaluation in dermatomyositis. Current management approaches include systemic glucocorticoids, conventional and emerging immunosuppressive therapies, and intravenous immunoglobulin. Moving forward, improved understanding of disease heterogeneity and immune pathways is expected to influence personalized approaches to diagnosis and treatment in dermatomyositis. This critical review article integrates current evidence on the epidemiology, clinical presentation, diagnostic framework, systemic association, and management of dermatomyositis, highlighting ongoing challenges and future directions in the care of this intricate autoimmune disorder.

## Linked entities

- **Diseases:** dermatomyositis (MONDO:0016367), interstitial lung disease (MONDO:0015925), malignancy (MONDO:0004992)

## Full-text entities

- **Genes:** IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, CXCL11 (C-X-C motif chemokine ligand 11) [NCBI Gene 6373] {aka H174, I-TAC, IP-9, IP9, SCYB11, SCYB9B}, TRIM33 (tripartite motif containing 33) [NCBI Gene 51592] {aka DDH4, ECTO, PTC7, RFG7, TF1G, TIF1G}, MORC3 (MORC family CW-type zinc finger 3) [NCBI Gene 23515] {aka NXP2, ZCW5, ZCWCC3}, KRT19 (keratin 19) [NCBI Gene 3880] {aka CK19, K19, K1CS}, IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}
- **Diseases:** erythema (MESH:D004890), fibrillation (MESH:D014693), immune dysregulation (OMIM:614878), amyopathic (MESH:C538250), renal complications (MESH:D007674), scalp erythema (MESH:D004476), autoimmune thyroid disease (MESH:D013967), ovarian, breast, colorectal, pancreatic, lung, and hematologic cancers (MESH:D010051), Cardiac involvement (MESH:D006331), muscle pain (MESH:D063806), Raynaud phenomenon (MESH:D011928), muscle injury (MESH:D009135), ILD (MESH:D017563), thromboembolic events (MESH:D013923), infertility (MESH:D007246), gastrointestinal intolerance (MESH:D005767), infection (MESH:D007239), conduction abnormalities (MESH:D054537), osteoporosis (MESH:D010024), weight loss (MESH:D015431), toxicity (MESH:D064420), arthralgias (MESH:D018771), thrombosis (MESH:D013927), Dysphagia (MESH:D003680), microvascular injury (MESH:D017566), cytopenias (MESH:D006402), hypertension (MESH:D006973), fever (MESH:D005334), Dermatomyositis (MESH:D003882), systemic sclerosis (MESH:D012595), lupus erythematosus (MESH:D008180), paraneoplastic syndrome (MESH:D010257), hypogammaglobulinemia (MESH:D000361), autoimmune disease (MESH:D001327), leukopenia (MESH:D007970), heliotrope rash (MESH:D005076), myocarditis (MESH:D009205), Myositis (MESH:D009220), Gottron's papules (MESH:C538187), fatigue (MESH:D005221), cancer (MESH:D009369), Muscular involvement (MESH:C538190), Muscle weakness (MESH:D018908), Pulmonary Disease (MESH:D008171), neurotoxicity (MESH:D020258), atrophy (MESH:D001284), muscle edema (MESH:D004487), hyperkeratosis (MESH:D017488), hepatitis B (MESH:D006509), poikiloderma (MESH:D011038), Calcinosis cutis (MESH:D000092182), muscle involvement (MESH:C566343), fibrosis (MESH:D005355), inflammation (MESH:D007249), cutaneous disease (MESH:D004194), capillary abnormalities (OMIM:163000), muscle (MESH:D019042), systemic autoimmune disease (MESH:D020274), like syndromes (MESH:C537419)
- **Chemicals:** baricitinib (MESH:C000596027), calcium (MESH:D002118), steroid (MESH:D013256), Rituximab (MESH:D000069283), heliotrope (-), cyclosporine (MESH:D016572), tacrolimus (MESH:D016559), cyclophosphamide (MESH:D003520), methotrexate (MESH:D008727), tofacitinib (MESH:C479163), azathioprine (MESH:D001379), Mycophenolate mofetil (MESH:D009173)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12948254/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12948254/full.md

## References

108 references — full list in the complete paper: https://tomesphere.com/paper/PMC12948254/full.md

---
Source: https://tomesphere.com/paper/PMC12948254